glp-1 agonists cardiovascular diseases Frontiers Frontiers | GLP-1 Receptor Agonists
Description
Eight-hundred and eighty-two (41%) received GLP-1RAs, and 1261 (59%) received control (placebo or insulin or no GLP-1RA)

doi: 10.1016/j.molmet.2018.09.009 64 BerndtSIGustafssonSMgiRGannaAWheelerEFeitosaMFet al

But GLP-1 agonists seemed to act differently: The direct administration of the drugs to AP, but not NST, caused weight loss

10.1152/physrev.00034.2006 57 HolstJ

This size is economical for the starting dose period since lower doses mean the vial lasts longer
These studies indicate that GLP-1 modulates the release of several neurotransmitters including serotonin, dopamine, GABA, and glutamate, which may regulate depressive-like behaviors
